Moreover, a progressive increase during the NAFLD pathogenesis is observed, as proven by the potential of circulating IL-6 levels to identify patients with simple steatosis (NAFL) to healthy controls (62), to identify patients with NASH as compared to those with simple steatosis (63), and to discriminate NASH patients with advanced fibrosis, from patients with no or mild fibrosis (64). Here, IL6 is linked to metabolic dysfunction-associated steatotic liver disease.